Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

•Most neuropathy observed with nab-paclitaxel plus gemcitabine (nab-P/Gem) was grades ≤II and none was grade IV.•≈ 16% of patients who received nab-P/Gem had dose modifications due to neuropathy.•Many patients who developed grade III neuropathy improved to grade ≤I in ≈ 1 month.•Patients who developed grade III versus lower grades of neuropathy had a longer median overall survival.